Skip to main content

Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).

Publication ,  Journal Article
Pond, GR; Armstrong, AJ; Wood, BA; Leopold, LH; Galsky, MD; Sonpavde, G
Published in: J Clin Oncol
February 10, 2012

204 Background: The efficacy of docetaxel following exposure to androgen synthesis inhibitors such as KC or abiraterone acetate (AA) is unknown. Given the emerging use of pre-docetaxel AA and docetaxel's inhibition of androgen signaling, we retrospectively evaluated the efficacy of every 3 week docetaxel with prednisone (DP) in mCRPC previously exposed to KC as compared to KC-naïve patients. METHODS: A randomized phase II trial of men with mCRPC treated with DP+AT-101 (bcl-2 inhibitor) vs. DP+placebo was analyzed (stratified for pain and performance status). Both arms were combined for analysis as no significant differences were seen. Overall survival [OS], progression-free survival [PFS], objective response [ORR], pain and PSA response rates were estimated with and without prior KC. RESULTS: Of 220 evaluable men, 40 (18.2%) received prior KC (median duration=2.0 months, maximum=31.1 months). These 40 men had less visceral disease (15% vs 28%), more prior radiotherapy (70% vs 51%), and increased prior radiological (38% vs 21%) or bone scan progression (55% vs 41%). Efficacy outcomes were not statistically different (table). After adjusting for baseline stratum and treatment group, prior KC did not appear to significantly change OS with DP-based therapy (HR 1.34, 95%CI: 0.86-2.09, p=0.20). CONCLUSIONS: Similar outcomes were observed in mCRPC treated with DP-based therapy with or without prior KC. Given the marginally inferior survival with prior KC, evaluation of docetaxel outcomes following AA is of clinical importance, given its more potent CYP17 inhibition. [Table: see text].

Duke Scholars

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 10, 2012

Volume

30

Issue

5_suppl

Start / End Page

204

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pond, G. R., Armstrong, A. J., Wood, B. A., Leopold, L. H., Galsky, M. D., & Sonpavde, G. (2012). Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). J Clin Oncol, 30(5_suppl), 204. https://doi.org/10.1200/jco.2012.30.5_suppl.204
Pond, G. R., A. J. Armstrong, B. A. Wood, L. H. Leopold, M. D. Galsky, and G. Sonpavde. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).J Clin Oncol 30, no. 5_suppl (February 10, 2012): 204. https://doi.org/10.1200/jco.2012.30.5_suppl.204.
Pond GR, Armstrong AJ, Wood BA, Leopold LH, Galsky MD, Sonpavde G. Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). J Clin Oncol. 2012 Feb 10;30(5_suppl):204.
Pond, G. R., et al. “Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC).J Clin Oncol, vol. 30, no. 5_suppl, Feb. 2012, p. 204. Pubmed, doi:10.1200/jco.2012.30.5_suppl.204.
Pond GR, Armstrong AJ, Wood BA, Leopold LH, Galsky MD, Sonpavde G. Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). J Clin Oncol. 2012 Feb 10;30(5_suppl):204.

Published In

J Clin Oncol

DOI

EISSN

1527-7755

Publication Date

February 10, 2012

Volume

30

Issue

5_suppl

Start / End Page

204

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences